Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 619
- Registration Number
- NCT03285763
- Locations
- 🇪🇸
Complejo Hospitalario de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain
🇬🇷Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine, Athens, Greece
🇮🇹Policlinico Umberto i di Roma; dip. Scienze Radiologiche, Oncologiche, Anatomopatologiche, Roma, Lazio, Italy
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
- Conditions
- Interventions
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 1550
- Registration Number
- NCT03281954
- Locations
- 🇺🇸
Waverly Hematology Oncology, Cary, North Carolina, United States
🇺🇸Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States
🇺🇸Meritus Center for Clinical Research, Hagerstown, Maryland, United States
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
- Conditions
- Interventions
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 410
- Registration Number
- NCT03281369
- Locations
- 🇺🇸
Uni of Southern California; Norris Comprehensive Cancer Ctr, Los Angeles, California, United States
🇺🇸Tennessee Oncology - Nashville, Nashville, Tennessee, United States
🇦🇺Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 136
- Registration Number
- NCT03276468
- Locations
- 🇫🇷
CHU de Caen, Caen, France
🇫🇷CHRU de Lille, Lille, France
🇫🇷CHU d'Angers, Angers, France
A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
- Conditions
- Interventions
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 446
- Registration Number
- NCT03273153
- Locations
- 🇺🇸
USC Norris Cancer Center; USC Oncology Hematology Newport Beach, Newport Beach, California, United States
🇺🇸Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Arjun Balar, MD
- Target Recruit Count
- 16
- Registration Number
- NCT03272217
- Locations
- 🇺🇸
University of Arizona at Dignity Health St. Joseph, Phoenix, Arizona, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸HealthPartners Institute, Minneapolis, Minnesota, United States
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 85
- Registration Number
- NCT03267940
- Locations
- 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 87
- Registration Number
- NCT03264066
- Locations
- 🇧🇪
AZ Groeninge, Kortrijk, Belgium
🇭🇺Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 35
- Registration Number
- NCT03262454
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
- Conditions
- Locally Advanced Ureter Urothelial CarcinomaMetastatic Ureter Urothelial CarcinomaRecurrent Ureter Urothelial CarcinomaStage III Bladder Cancer AJCC v8Stage III Ureter Cancer AJCC v8Locally Advanced Urethral Urothelial CarcinomaRecurrent Renal Pelvis Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Urethral Urothelial CarcinomaRecurrent Bladder Urothelial Carcinoma
- Interventions
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 72
- Registration Number
- NCT03237780
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.